 Hubriphar, S.A.
Hubriphar has been incorporated as a Belgian limited liability company founded in 1992. Hubriphar owns 4 shares of H-Phar. Hubriphar has contributed in kind with HIV/AIDS and Immunology licences, its family of molecules and all its derivatives for all applications. The valuation related to the contribution in kind has been established based on real costs and was confirmed by an Auditor as requested by the Belgian Law. Hubriphar and H-Phar entered into a consulting agreement whereby Hubriphar offers, through Mrs. Margery and Dr. Vandevelde, to the Company, management services on a daily basis.
Mrs Hélène Margery co inventor owns 1533 shares of H-Phar (23,2%) , she is Chief Executive Officer
Mr Michel Vandevelde MD co inventor owns 1080 shares of H-Phar(16,3%), he is Chairman of the Board
Avenue Joseph Wybran., 40, B-1070 Brussels, Belgium.
Tel: + 32.2.529.58.33 - fax: + 32.2.529.59.11.
http://www.hubriphar.com
S.R.I.W. SA Société Régionale d’Investissement de Wallonie SA
The SRIW and its subsidiaries together form the SRIW Group, whose mission is to intervene financially for the long term, in companies not only in Belgium but also abroad, with the objective of promoting the economic development of the Walloon Region, either directly or indirectly. They participate in projects for redeployment, modernisation or growth of the companies concerned. The financial resources which they contribute to the companies concentrate on activities aimed at the long term. This contrasts with the conventional, short-term financing covered by traditional bankers. SRIW owns 1102 shares of H-Phar( 16%)
Avenue Destenay, 13- 4000 LIEGE Belgium
Phone : (32) 04/221.98.11 - Fax : (32) 04/221.99.99
http://www.sriw.be
Sambrinvest s.a. Société de Développement et de Participation du Bassin de Charleroi
Sambrinvest and its subsidiaries are a source of venture capital to support the development of SME in the Charleroi and Thuin districts. Sambrinvest s.a. was established in 1985 with a view to participating in the reconstruction and the renovation of the Charleroi Basin, badly affected by numerous losses of jobs in the steel-industry. Its vocation is to provide venture capital for SME that are in start up situation, are in a development stage or where ownership is being transferred. Its investment criteria are that the SME involved are able to provide added value and create employment. Venture Captial Fund – Objective n°1 s.a. owns 729 shares of H-Phar(11%) and Sambrinvest Spin Off-Spin Out owns 373 shares of H-Phar(5.6%). Sambrinvest invest in H-Phar through its Subsidiaries
|
VENTURE CAPITAL FUND – Objective n°1 s.a. (FEDER - Objective 1 – Hainaut) : support to SME being set up or in a development stage
Sambrinvest Spin Off-Spin Out : supporting emergence of companies from Universities or other Companies
|
Avenue Georges Lemaître, 62 – Aéropôle - 6041 GOSSELIES Belgium
Phone. : (32) 071/25.94.94 - Fax : (32) 071/25.94.99
http://www.sambrinvest.be
Florinvest , S.A.
Florinvest is the Life Science and Biotechnological division of the holding Floridienne. Floridienne is quoted on the Euronext ( Brussels). In addition to its industrial productions, it includes risk capital and development activities. It makes investments in the chemical, biotechnological and food-processing fields, relating to the other activities of the group. Florinvest actively develops its activities in the life sciences. Thanks to its environment, its financial and industrial activities, Florinvest is an added value investor. Florinvest owns 623 shares of H-Phar(9.4%). Florinvest assists the management of H-Phar and participates to the fund raising and the negotiations with investors or partners.
Avenue de Tervuren, 198 F, B - 1410 Waterloo, Belgium.
Tel: + 32.2.353.00.28 - fax: + 32.2.353.05.81.
http://www.floridienne.be
Université Libre de Bruxelles, (U.L.B).
The U.L.B. owns 376 shares of H-Phar(5,7%).The « Université Libre de Bruxelles » was founded in 1834 and has built a strong tradition in education and research.18.000 students are registered at the ULB, one third come from abroad, among which half of them from European Union.The ULB conducts fundamental and applied researches. Over € 50 million are allocated to research each year, thanks to contracts with private companies and public authorities.The ULB has a distinguished record for excellence in research. Three out of the six Belgian Nobel Prize (J. Bordet, Medicine, 1919, A. Claude, Medicine, 1974 and I. Prigogine, Chemistry, 1977) or Fields Medal recipients were ULB professors. During the last twenty years, seven Francqui Prize, the “Belgian” Nobel Prize was awarded to members of the ULB.
Avenue Franklin Roosevelt, 50 , B - 1050 Brussels, Belgium.
Tel: + 32.2.650.21.11.
http://www.ulb.ac.be
Metrobel SA (Filiale à 100% de la compagnie du Bois Sauvage)
Metrobel. owns 800 shares of H-Phar(12%). "Compagnie du Bois Sauvage" is a holding company incorporated under Belgian law, listed on Euronext Brussels, with a stable, “family” majority shareholder.
Its object is to acquire participating interests in both listed and unlisted companies.
Its aim is to support talented businessmen and women, whether financiers or industrialists who at some time during their company’s existence seek support.
Rue du Bois Sauvage, 17, B-1000 Brussels, Belgium Tél. :+32(0)2.227.54.50 info@bois-sauvage.be
|
